Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer

Prostate

Volumn 72, Issue 13, 2012, Pages 1469-1477

  Shen, Jing ^a   Hruby, Gregory W ^b   McKiernan, James M ^b   Gurvich, Irina ^a   Lipsky, Michael Jeffrey ^b   Benson, Mitchell C ^b   Santella, Regina M ^a  

^a Department of Medicine   (United States)

^b Department of Medicine   (United States)

Author keywords

aggressiveness; miRNAs; prediction; prostate cancer

Indexed keywords

BIOLOGICAL MARKER; MICRORNA 145; MICRORNA 20A; MICRORNA 21; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGGRESSIVE PROSTATE CANCER; ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE OVEREXPRESSION; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

AGED; DISEASE PROGRESSION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; QUESTIONNAIRES; TUMOR MARKERS, BIOLOGICAL;

EID: 84864877232     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22499     Document Type: Article

References (43)

1. Coppola V, De Maria R, Bonci D,. MicroRNAs and prostate cancer. Endocr Relat Cancer 2010; 17 (1): F1-F17.
2. Le XF, Merchant O, Bast RC, Calin GA,. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron 2010; 3 (1): 137-147.
3. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spangberg A, Palmgren J, Steineck G, Adami HO, Johansson JE,. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364 (18): 1708-1717.
4. Bartel DP,. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
5. Lai EC,. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 2002; 30 (4): 363-364.
6. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da P I, Gunsalus KC, Stoffel M, Rajewsky N,. Combinatorial microRNA target predictions. Nat Genet 2005; 37 (5): 495-500. (Pubitemid 40617277)
7. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY,. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18 (10): 997-1006.
8. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A,. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008; 3 (9): e3148.
9. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X,. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2009; 127: 118-126.
10. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M,. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105 (30): 10513-10518.
11. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S,. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009; 2 (9): 807-813.
12. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sultmann H,. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011; 128 (3): 608-616.
13. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH, Ye DW,. Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011; 71 (3): 326-331.
14. Pesta M, Klecka J, Kulda V, Topolcan O, Hora M, Eret V, Ludvikova M, Babjuk M, Novak K, Stolz J, Holubec L,. Importance of miR-20a expression in prostate cancer tissue. Anticancer Res 2010; 30 (9): 3579-3583.
15. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, Riedmiller H, Kneitz B,. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010; 127 (2): 394-403.
16. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Dall'oglio MF, Camara-Lopes LH, Srougi M,. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol 2011 Aug 29. [Epub ahead of print].
17. Cooperberg MR, Broering JM, Carroll PR,. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009; 101 (12): 878-887.
18. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 1998; 280 (11): 969-974. (Pubitemid 28445094)
19. D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP,. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002; 95 (2): 281-286. (Pubitemid 34787593)
20. Chakravarti IM, Laha RG, Roy J,. Handbook of methods of applied statistics. New York: John Wiley; 1967. pp. 392-394.
21. Zweig MH, Campbell G,. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39 (4): 561-577. (Pubitemid 23118304)
22. Moltzahn F, Olshen AB, Baehner L, Peek AS, Fong L, Stoppler HJ, Simko J, Hilton JF, Carroll PR, Blelloch R,. Microfluidic based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in sera of prostate cancer patients. Cancer Res 2011; 71 (2): 550-560.
23. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, Gezer U,. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 2011; 32 (3): 583-588.
24. Sylvestre Y, De G V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G, Chartrand P,. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem 2007; 282 (4): 2135-2143. (Pubitemid 47076740)
25. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM,. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103 (7): 2257-2261. (Pubitemid 43271657)
26. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, Kung HF, Lai L, Jiang BH,. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS ONE 2011; 6 (4): e19139.
27. Arbuzova A, Schmitz AA, Vergeres G,. Cross-talk unfolded: MARCKS proteins. Biochem J 2002; 362 (Pt 1): 1-12. (Pubitemid 34174456)
28. Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, Dyrskjot L, Eltze E, Wieland W, Keck B, Ekici AB, Grasser F, Wullich B,. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 2011; 130 (3): 611-621.
29. Ozen M, Creighton CJ, Ozdemir M, Ittmann M,. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27 (12): 1788-1793. (Pubitemid 351380263)
30. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T,. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67 (13): 6130-6135. (Pubitemid 47037493)
31. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K,. Mo YY. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106 (9): 3207-3212.
32. Sachdeva M, Mo YY,. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70 (1): 378-387.
33. Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ, Thibodeau SN,. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 2009; 69 (24): 9490-9497.
34. Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ, Chun KH,. Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 2011; 155 (3): 427-434.
35. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'Incalci M,. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections. Lancet Oncol 2011; 12 (3): 273-285.
36. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y, Dahiya R,. The functional significance of microRNA-145 in prostate cancer. Br J Cancer 2010; 103 (2): 256-264.
37. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, Farace MG,. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007; 282 (32): 23716-23724. (Pubitemid 47311902)
38. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, Spagnoli LG, Farace MG, Ciafre SA,. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE 2008; 3 (12): e4029.
39. Zheng C, Yinghao S, Li J,. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Med Oncol 2011 Apr 13. [Epub ahead of print].
40. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K,. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126 (5): 1166-1176.
41. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P,. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009; 69 (8): 3356-3363.
42. Chen Y, Zaman MS, Deng G, Majid S, Saini S, Liu J, Tanaka Y, Dahiya R,. MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila) 2011; 4 (1): 76-86.
43. Lughezzani G, Budaus L, Isbarn H, Sun M, Perrotte P, Haese A, Chun FK, Schlomm T, Steuber T, Heinzer H, Huland H, Montorsi F, Graefen M, Karakiewicz PI,. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol 2010; 57 (4): 562-568.